{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:33:21Z","timestamp":1792895601513,"version":"4.5.0"},"reference-count":149,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.tranon.2021.101081","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T23:19:11Z","timestamp":1618355951000},"page":"101081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Thrombotic microangiopathy in oncology \u2013 a review"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7397-0233","authenticated-orcid":false,"given":"Patr\u00edcia","family":"Val\u00e9rio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5175-844X","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4002-0965","authenticated-orcid":false,"given":"Teresa","family":"Chuva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Maximino","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.tranon.2021.101081_bib0001","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2021.101081_bib0002","first-page":"21","article-title":"Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease","volume":"24","author":"Moschcowitz","year":"1924","journal-title":"Proc. N Y Pathol. Soc."},{"issue":"6","key":"10.1016\/j.tranon.2021.101081_bib0003","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood.V2.6.542.542","article-title":"Thrombotic thrombocytopenic purpura; hemorrhagic diathesis with generalized platelet thromboses","volume":"2","author":"Singer","year":"1947","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.tranon.2021.101081_bib0004","first-page":"211","article-title":"Portuguese consensus document statement in diagnostic and management of atypical hemolytic uremic syndrome","volume":"32","author":"Azevedo","year":"2018","journal-title":"Port J. Nephrol. Hypert."},{"issue":"4","key":"10.1016\/j.tranon.2021.101081_bib0005","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1055\/s-0039-1687893","article-title":"Thrombotic Microangiopathy in cancer","volume":"45","author":"Weitz","year":"2019","journal-title":"Semin. Thromb Hemost."},{"issue":"5","key":"10.1016\/j.tranon.2021.101081_bib0006","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","article-title":"Thrombotic microangiopathy, cancer, and cancer drugs","volume":"66","author":"Izzedine","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.tranon.2021.101081_bib0007","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-3-030-20315-3_10","article-title":"Microangiopathy in cancer: causes, consequences, and management","volume":"179","author":"Thomas","year":"2019","journal-title":"Cancer Treat Res."},{"issue":"6","key":"10.1016\/j.tranon.2021.101081_bib0008","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/j.ajkd.2018.06.013","article-title":"Emerging concepts in hematopoietic stem cell transplantation-associated renal thrombotic microangiopathy and prospects for new treatments","volume":"72","author":"Wanchoo","year":"2018","journal-title":"Am. J. Kidney Dis."},{"issue":"3","key":"10.1016\/j.tranon.2021.101081_bib0009","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \"kidney disease: improving global outcomes\" (kdigo) controversies conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.tranon.2021.101081_bib0010","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the american society for apheresis: the eighth special issue","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J. Clin. Apher."},{"issue":"1","key":"10.1016\/j.tranon.2021.101081_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-016-3123-6","article-title":"Rituximab to treat gemcitabine-induced hemolytic-uremic syndrome (Hus) in pancreatic adenocarcinoma: a case series and literature review","volume":"79","author":"Ritchie","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"16","key":"10.1016\/j.tranon.2021.101081_bib0012","first-page":"30178","article-title":"Gemcitabine-associated thrombotic microangiopathy: response to complement inhibition and reinitiation of gemcitabine","volume":"20","author":"Turner","year":"2016","journal-title":"Clin. Colorectal Cancer"},{"issue":"4","key":"10.1016\/j.tranon.2021.101081_bib0013","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1053\/ajkd.2002.35758","article-title":"Gemcitabine-associated hemolytic-uremic syndrome","volume":"40","author":"Walter","year":"2002","journal-title":"Am. J. Kidney Dis."},{"issue":"6","key":"10.1016\/j.tranon.2021.101081_bib0014","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1200\/JOP.2016.012096","article-title":"Microangiopathic hemolytic anemia and thrombocytopenia in patients with cancer","volume":"12","author":"Morton","year":"2016","journal-title":"J. Oncol. Pract."},{"key":"10.1016\/j.tranon.2021.101081_bib0015","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fmed.2020.00212","article-title":"An update in drug-induced thrombotic microangiopathy","volume":"7","author":"Chatzikonstantinou","year":"2020","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.tranon.2021.101081_bib0016","series-title":"Common Terminology Criteria for Adverse Events (Ctcae) - Version 5.0","year":"2017"},{"key":"10.1016\/j.tranon.2021.101081_bib0017","unstructured":"Mitomycin-C Pulmonary Toxicity [Internet]. (Accessed July 16, 2020). 2020. Available from: https:\/\/www.uptodate.com\/contents\/mitomycin-c-pulmonary-toxicity?search=Mitomycin%20C&source=search_result&selectedTitle=2~106&usage_type=default&display_rank=1."},{"issue":"5","key":"10.1016\/j.tranon.2021.101081_bib0018","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/1097-0142(1971)28:5<1314::AID-CNCR2820280534>3.0.CO;2-D","article-title":"Renal toxicity in man treated with mitomycin C","volume":"28","author":"Liu","year":"1971","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2021.101081_bib0019","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/1097-0142(19850101)55:1<47::AID-CNCR2820550108>3.0.CO;2-#","article-title":"Renal complications of mitomycin c therapy with special reference to the total dose","volume":"55","author":"Valavaara","year":"1985","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.tranon.2021.101081_bib0020","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1526-0968.2003.00127.x","article-title":"Drug-induced thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome: a concise review","volume":"8","author":"Dlott","year":"2004","journal-title":"Ther. Apher. Dial"},{"issue":"1","key":"10.1016\/j.tranon.2021.101081_bib0021","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0167-8140(87)80020-8","article-title":"Mitomycin C-induced hemolytic uremic syndrome. six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drug","volume":"8","author":"Verweij","year":"1987","journal-title":"Radiother. Oncol."},{"issue":"2","key":"10.1016\/j.tranon.2021.101081_bib0022","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jvir.2008.10.025","article-title":"Successful treatment of mitomycin-induced thrombotic thrombocytopenic purpura with rituximab","volume":"20","author":"Onitilo","year":"2009","journal-title":"J. Vasc. Interv. Radiol."},{"issue":"6","key":"10.1016\/j.tranon.2021.101081_bib0023","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1200\/JCO.1989.7.6.781","article-title":"Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry","volume":"7","author":"Lesesne","year":"1989","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.tranon.2021.101081_bib0024","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ajh.23960","article-title":"Drug-induced thrombotic microangiopathy: experience of the oklahoma registry and the bloodcenter of Wisconsin","volume":"90","author":"Reese","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.tranon.2021.101081_bib0025","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/1097-0142(19861001)58:7<1428::AID-CNCR2820580709>3.0.CO;2-J","article-title":"A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma","volume":"58","author":"Sheldon","year":"1986","journal-title":"Cancer"},{"issue":"25\u201326","key":"10.1016\/j.tranon.2021.101081_bib0026","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1055\/s-2003-40105","article-title":"Mitomycin-induced hemolytic-uremic syndrome","volume":"128","author":"Zeller","year":"2003","journal-title":"Dtsch Med. Wochenschr"},{"key":"10.1016\/j.tranon.2021.101081_bib0027","article-title":"Mitomycin-C-induced Ttp\/hus treated successfully with rituximab: case report and review of the literature","volume":"2013","author":"Shah","year":"2013","journal-title":"Case Rep. Hematol."},{"issue":"5","key":"10.1016\/j.tranon.2021.101081_bib0028","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ckj\/sft078","article-title":"Eculizumab and drug-induced haemolytic-uraemic syndrome","volume":"6","author":"Faguer","year":"2013","journal-title":"Clin. Kidney J."},{"issue":"1","key":"10.1016\/j.tranon.2021.101081_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000495031","article-title":"Treatment of chemotherapy-induced thrombotic microangiopathy with eculizumab in a patient with metastatic breast cancer","volume":"12","author":"Hausberg","year":"2019","journal-title":"Case Rep. Oncol."},{"issue":"11","key":"10.1016\/j.tranon.2021.101081_bib0030","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1093\/ndt\/gfl507","article-title":"Gemcitabine-induced thrombotic microangiopathy: a systematic review","volume":"21","author":"Izzedine","year":"2006","journal-title":"Nephrol. Dial Trans."},{"issue":"2","key":"10.1016\/j.tranon.2021.101081_bib0031","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5414\/CNP71130","article-title":"Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution","volume":"71","author":"Glezerman","year":"2009","journal-title":"Clin. Nephrol."},{"issue":"3","key":"10.1016\/j.tranon.2021.101081_bib0032","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1517\/14740330902942299","article-title":"Thrombotic microangiopathy associated with gemcitabine: rare but real","volume":"8","author":"Saif","year":"2009","journal-title":"Expert Opin Drug Saf."},{"issue":"9","key":"10.1016\/j.tranon.2021.101081_bib0033","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9%3C2023::AID-CNCR21%3E3.0.CO;2-2","article-title":"A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy","volume":"85","author":"Fung","year":"1999","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.tranon.2021.101081_bib0034","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.nephro.2017.01.023","article-title":"Thrombotic microangiopathy and cancer","volume":"13","author":"Kheder El-Fekih","year":"2017","journal-title":"Nephrol. Ther."},{"issue":"2017","key":"10.1016\/j.tranon.2021.101081_bib0035","doi-asserted-by":"crossref","first-page":"100","DOI":"10.5414\/CN108838","article-title":"Gemcitabine-induced hemolytic-uremic syndrome treated with eculizumab or plasmapheresis: two case reports","volume":"87","author":"L\u00f3pez Rubio","year":"2017","journal-title":"Clin. Nephrol."},{"issue":"1","key":"10.1016\/j.tranon.2021.101081_bib0036","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00280-008-0900-x","article-title":"Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report","volume":"64","author":"Bharthuar","year":"2009","journal-title":"Cancer Chemother Pharmacol."},{"issue":"5","key":"10.1016\/j.tranon.2021.101081_bib0037","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00280-010-1258-4","article-title":"Rapid and complete resolution of chemotherapy-induced thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome (ttp\/hus) with rituximab","volume":"65","author":"Gourley","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.tranon.2021.101081_bib0038","first-page":"2078","article-title":"Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review","volume":"5","author":"Al Ustwani","year":"2014","journal-title":"J. Gastrointest Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2021.101081_bib0039","doi-asserted-by":"crossref","first-page":"018","DOI":"10.1186\/s12882-018-0812-x","article-title":"The use of eculizumab in gemcitabine induced thrombotic microangiopathy","volume":"19","author":"Krishnappa","year":"2018","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.tranon.2021.101081_bib0040","unstructured":"Cisplatin Nephrotoxicity [Internet]. (Accessed July 16, 2020). 2020. Available from: https:\/\/www.uptodate.com\/contents\/cisplatin-nephrotoxicity?search=Cisplatin%20nephrotoxicity&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1."},{"issue":"4","key":"10.1016\/j.tranon.2021.101081_bib0041","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/ckj\/sft065","article-title":"Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of Cd46 treated with eculizumab","volume":"6","author":"Gilbert","year":"2013","journal-title":"Clin. Kidney J."},{"issue":"2\u20133","key":"10.1016\/j.tranon.2021.101081_bib0042","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/08860228909066955","article-title":"Hemolytic uremic syndrome following cisplatin, bleomycin, and vincristine chemotherapy: a report of a case and a review of the literature","volume":"11","author":"Gardner","year":"1989","journal-title":"Ren. Fail"},{"issue":"1","key":"10.1016\/j.tranon.2021.101081_bib0043","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7326\/0003-4819-101-1-41","article-title":"Thrombotic Microangiopathy and renal failure associated with antineoplastic chemotherapy","volume":"101","author":"Jackson","year":"1984","journal-title":"Ann. Intern Med."},{"issue":"12","key":"10.1016\/j.tranon.2021.101081_bib0044","first-page":"4501","article-title":"Evidence for acute vascular toxicity of cisplatin-based chemotherapy in patients with germ cell tumour","volume":"31","author":"Dieckmann","year":"2011","journal-title":"Anticancer Res."},{"issue":"11","key":"10.1016\/j.tranon.2021.101081_bib0045","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1002\/1097-0142(19941201)74:11<3059::AID-CNCR2820741125>3.0.CO;2-Z","article-title":"Cisplatin-associated hemolytic uremic syndrome","volume":"74","author":"Canpolat","year":"1994","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.tranon.2021.101081_bib0046","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/1097-0142(19901101)66:9<1914::AID-CNCR2820660910>3.0.CO;2-G","article-title":"Chemotherapy-related hemolytic-uremic syndrome after the treatment of head and neck cancer. a case report","volume":"66","author":"Gradishar","year":"1990","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.tranon.2021.101081_bib0047","doi-asserted-by":"crossref","first-page":"439","DOI":"10.21873\/invivo.11080","article-title":"Thrombotic microangiopathy following chemotherapy with S-1 and cisplatin in a patient with gastric cancer: a case report","volume":"31","author":"Muto","year":"2017","journal-title":"In Vivo (Brooklyn)"},{"issue":"2","key":"10.1016\/j.tranon.2021.101081_bib0048","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1053\/ajkd.1998.v32.pm9708619","article-title":"Successful treatment of cisplatin-induced hemolytic uremic syndrome with therapeutic plasma exchange","volume":"32","author":"Palmisano","year":"1998","journal-title":"Am. J. Kidney Dis."},{"issue":"31","key":"10.1016\/j.tranon.2021.101081_bib0049","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1200\/JCO.2012.42.5082","article-title":"Oxaliplatin-induced thrombotic thrombocytopenic purpura: case report and literature review","volume":"30","author":"Niu","year":"2012","journal-title":"J. Clin. Oncol"},{"issue":"1","key":"10.1016\/j.tranon.2021.101081_bib0050","first-page":"5","article-title":"Atypical Hemolytic uremic syndrome related to oxalyplatin cancer chemotherapy responsive to eculizumab","volume":"34","author":"Zanchelli","year":"2017","journal-title":"G Ital Nefrol."},{"issue":"2","key":"10.1016\/j.tranon.2021.101081_bib0051","doi-asserted-by":"crossref","first-page":"013","DOI":"10.1007\/s12032-013-0568-x","article-title":"Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage her2+ breast cancer: a case report","volume":"30","author":"Iams","year":"2013","journal-title":"Med. Oncol."},{"issue":"6","key":"10.1016\/j.tranon.2021.101081_bib0052","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/00001813-199907000-00004","article-title":"Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine","volume":"10","author":"Gross","year":"1999","journal-title":"Anticancer Drugs"},{"issue":"5","key":"10.1016\/j.tranon.2021.101081_bib0053","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/1097-0142(19890901)64:5<1017::AID-CNCR2820640508>3.0.CO;2-N","article-title":"Carboplatin-associated thrombotic microangiopathic hemolytic anemia","volume":"64","author":"Walker","year":"1989","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2021.101081_bib0054","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/ki.2013.408","article-title":"Pegylated liposomal doxorubicin and renal thrombotic microangiopathy: an under-recognized complication of prolonged treatment for ovarian cancer","volume":"85","author":"Shavit","year":"2014","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.tranon.2021.101081_bib0055","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin. Pharmacokinet"},{"issue":"12","key":"10.1016\/j.tranon.2021.101081_bib0056","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1634\/theoncologist.2011-0422","article-title":"Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?","volume":"17","author":"Kwa","year":"2012","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.tranon.2021.101081_bib0057","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/bjh.14910","article-title":"Effective treatment of chemotherapy induced atypical haemolytic uraemic syndrome: a case series of 7 treated patients","volume":"183","author":"Weitz","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.tranon.2021.101081_bib0058","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s12032-009-9333-6","article-title":"Thrombotic microangiopathy following docetaxel and trastuzumab chemotherapy: a case report","volume":"27","author":"Siau","year":"2010","journal-title":"Med. Oncol."},{"issue":"5","key":"10.1016\/j.tranon.2021.101081_bib0059","doi-asserted-by":"crossref","DOI":"10.1097\/MJT.0b013e3181cea0b3","article-title":"Docetaxel-induced thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome-related complex in a patient with metastatic prostate cancer?","volume":"18","author":"Shrestha","year":"2011","journal-title":"Am. J. Ther."},{"issue":"9","key":"10.1016\/j.tranon.2021.101081_bib0060","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3324\/haematol.2015.128793","article-title":"Renal complications in chronic lymphocytic leukemia and monoclonal b-cell lymphocytosis: the mayo clinic experience","volume":"100","author":"Strati","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.tranon.2021.101081_bib0061","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ekir.2016.09.055","article-title":"Adverse renal effects of novel molecular oncologic targeted therapies: a narrative review","volume":"2","author":"Jhaveri","year":"2016","journal-title":"Kidney Int. Rep."},{"issue":"24","key":"10.1016\/j.tranon.2021.101081_bib0062","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MD.0000000000000207","article-title":"Kidney diseases associated with anti-vascular endothelial growth factor (vegf): an 8-year observational study at a single center","volume":"93","author":"Izzedine","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"10.1016\/j.tranon.2021.101081_bib0063","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"Vegf inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.tranon.2021.101081_bib0064","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/ndt\/gft465","article-title":"All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a rare study","volume":"29","author":"Vigneau","year":"2014","journal-title":"Nephrol. Dial Trans."},{"issue":"1","key":"10.1016\/j.tranon.2021.101081_bib0065","first-page":"2","article-title":"Bevacizumab-mediated interference with Vegf signaling is sufficient to induce a preeclampsia-like syndrome in nonpregnant women","volume":"5","author":"Cross","year":"2012","journal-title":"Rev. Obstet Gynecol."},{"key":"10.1016\/j.tranon.2021.101081_bib0066","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.biopha.2018.10.082","article-title":"Preeclampsia: a close look at renal dysfunction","volume":"109","author":"Moghaddas Sani","year":"2019","journal-title":"Biomed Pharmacother."},{"issue":"2","key":"10.1016\/j.tranon.2021.101081_bib0067","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/ndt\/gfn657","article-title":"Thrombotic microangiopathy secondary to Vegf pathway inhibition by sunitinib","volume":"24","author":"Bollee","year":"2009","journal-title":"Nephrol. Dial Trans."},{"issue":"4","key":"10.1016\/j.tranon.2021.101081_bib0068","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1177\/1078155218774895","article-title":"Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab","volume":"25","author":"Vakiti","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"18","key":"10.1016\/j.tranon.2021.101081_bib0069","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1158\/1078-0432.CCR-11-0804","article-title":"Thrombotic microangiopathy with targeted cancer agents","volume":"17","author":"Blake-Haskins","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.tranon.2021.101081_bib0070","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/jnci\/djm311","article-title":"A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib","volume":"100","author":"Patel","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"issue":"10","key":"10.1016\/j.tranon.2021.101081_bib0071","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/annonc\/mdm454","article-title":"Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome","volume":"18","author":"Kapiteijn","year":"2007","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.tranon.2021.101081_bib0072","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/1078155214568580","article-title":"Secondary thrombotic microangiopathy in two patients with philadelphia-positive hematological malignancies treated with imatinib mesylate","volume":"22","author":"Ojeda-Uribe","year":"2016","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"4","key":"10.1016\/j.tranon.2021.101081_bib0073","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1053\/j.ajkd.2004.12.017","article-title":"Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate: true association or mere coincidence?","volume":"45","author":"Al Aly","year":"2005","journal-title":"Am. J. Kidney Dis."},{"issue":"9","key":"10.1016\/j.tranon.2021.101081_bib0074","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1200\/JCO.2008.19.0108","article-title":"Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma","volume":"27","author":"Feldman","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.tranon.2021.101081_bib0075","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ajh.24447","article-title":"Proteasome inhibitor associated thrombotic microangiopathy","volume":"91","author":"Yui","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.tranon.2021.101081_bib0076","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/ckj\/sfv059","article-title":"Thrombotic microangiopathy associated with proteasome inhibitors","volume":"8","author":"Lodhi","year":"2015","journal-title":"Clin. Kidney J."},{"issue":"3","key":"10.1016\/j.tranon.2021.101081_bib0077","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2147\/tcrm.2006.2.3.271","article-title":"Bortezomib (velcadetrade mark) in the treatment of multiple myeloma","volume":"2","author":"Field-Smith","year":"2006","journal-title":"Ther. Clin. Risk Manag."},{"issue":"4","key":"10.1016\/j.tranon.2021.101081_bib0078","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/1078155214531804","article-title":"Carfilzomib-related acute kidney injury may be prevented by N-acetyl-l-cysteine","volume":"21","author":"Wanchoo","year":"2015","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"4","key":"10.1016\/j.tranon.2021.101081_bib0079","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1445-5994.2011.02458.x","article-title":"Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib","volume":"41","author":"Moore","year":"2011","journal-title":"Intern Med. J."},{"issue":"9","key":"10.1016\/j.tranon.2021.101081_bib0080","doi-asserted-by":"crossref","first-page":"E241","DOI":"10.1002\/ajh.25208","article-title":"Drug-induced thrombotic microangiopathy: an updated systematic review, 2014\u20132018","volume":"93","author":"Saleem","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.tranon.2021.101081_bib0081","article-title":"Drug-induced thrombotic microangiopathy due to cumulative toxicity of ixazomib","volume":"2018","author":"Atallah-Yunes","year":"2018","journal-title":"Case Rep. Hematol."},{"issue":"4","key":"10.1016\/j.tranon.2021.101081_bib0082","doi-asserted-by":"crossref","first-page":"E53","DOI":"10.1002\/ajh.24662","article-title":"Ixazomib-induced thrombotic microangiopathy","volume":"92","author":"Yui","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.tranon.2021.101081_bib0083","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/ccr3.1214","article-title":"Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life-saving treatment","volume":"5","author":"Gosain","year":"2017","journal-title":"Clin. Case Rep."},{"issue":"23","key":"10.1016\/j.tranon.2021.101081_bib0084","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1182\/bloodadvances.2018027532","article-title":"Carfilzomib-induced Ahus responds to early eculizumab and may be associated with heterozygous Cfhr3-Cfhr1 deletion","volume":"2","author":"Portuguese","year":"2018","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.tranon.2021.101081_bib0085","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.tranon.2021.101081_bib0086","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12882-018-1194-9","article-title":"Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report","volume":"20","author":"Yamada","year":"2019","journal-title":"BMC Nephrol."},{"issue":"1","key":"10.1016\/j.tranon.2021.101081_bib0087","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5414\/CN108901","article-title":"Thrombotic microangiopathy associated with cetuximab, an epidermal growth factor receptor inhibitor","volume":"87","author":"Koizumi","year":"2017","journal-title":"Clin. Nephrol."},{"issue":"9","key":"10.1016\/j.tranon.2021.101081_bib0088","first-page":"20","article-title":"Transplant-associated thrombotic microangiopathy: incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation","volume":"32","author":"Gavriilaki","year":"2018","journal-title":"Clin. Trans."},{"issue":"6","key":"10.1016\/j.tranon.2021.101081_bib0089","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1055\/s-2005-925475","article-title":"Thrombotic microangiopathy in transplantation and malignancy","volume":"31","author":"Qu","year":"2005","journal-title":"Semin. Thromb Hemost."},{"issue":"1","key":"10.1016\/j.tranon.2021.101081_bib0090","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.bmt.1701830","article-title":"Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. gruppo italiano trapianto midollo osseo (Gitmo)","volume":"24","author":"Iacopino","year":"1999","journal-title":"Bone Marrow Trans."},{"issue":"2","key":"10.1016\/j.tranon.2021.101081_bib0091","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1537-2995.2004.00700.x","article-title":"Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic Hpc transplantation: a diagnostic dilemma","volume":"44","author":"George","year":"2004","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.tranon.2021.101081_bib0092","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1053\/j.seminhematol.2018.04.003","article-title":"Complement in pathophysiology and treatment of transplant-associated thrombotic microangiopathies","volume":"55","author":"Jodele","year":"2018","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.tranon.2021.101081_bib0093","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3389\/fimmu.2019.00337","article-title":"Complement in thrombotic microangiopathies: unraveling ariadne's thread into the labyrinth of complement therapeutics","volume":"10","author":"Gavriilaki","year":"2019","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.tranon.2021.101081_bib0094","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/bmt.2014.17","article-title":"Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving Gvhd prophylaxis with tacrolimus plus Mtx or sirolimus","volume":"49","author":"Labrador","year":"2014","journal-title":"Bone Marrow Trans."},{"issue":"2","key":"10.1016\/j.tranon.2021.101081_bib0095","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.bbmt.2012.10.006","article-title":"Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus\/sirolimus-based graft-versus-host disease prophylaxis","volume":"19","author":"Shayani","year":"2013","journal-title":"Biol Blood Marrow Trans."},{"issue":"4","key":"10.1016\/j.tranon.2021.101081_bib0096","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/bmt.2009.230","article-title":"Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning","volume":"45","author":"Willems","year":"2010","journal-title":"Bone Marrow Trans."},{"issue":"2","key":"10.1016\/j.tranon.2021.101081_bib0097","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2215\/CJN.02070508","article-title":"Renal thrombotic microangiopathy after hematopoietic cell transplant: role of Gvhd in pathogenesis","volume":"4","author":"Changsirikulchai","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.tranon.2021.101081_bib0098","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/sj.bmt.1702849","article-title":"Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes","volume":"27","author":"Roy","year":"2001","journal-title":"Bone Marrow Trans."},{"issue":"6","key":"10.1016\/j.tranon.2021.101081_bib0099","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2011-02-321315","article-title":"Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"118","author":"Laskin","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.tranon.2021.101081_bib0100","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/TP.0000000000000601","article-title":"Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the Sfgm-Tc","volume":"99","author":"de Fontbrune","year":"2015","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.tranon.2021.101081_bib0101","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/bjh.12202","article-title":"Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy","volume":"161","author":"Peffault de Latour","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.tranon.2021.101081_bib0102","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbmt.2013.12.565","article-title":"Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"20","author":"Jodele","year":"2014","journal-title":"Biol Blood Marrow Trans."},{"issue":"13","key":"10.1016\/j.tranon.2021.101081_bib0103","first-page":"1049","article-title":"Complement blockade for Ta-Tma: lessons learned from a large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.tranon.2021.101081_bib0104","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.transci.2016.04.007","article-title":"New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"54","author":"Jodele","year":"2016","journal-title":"Transfus Apher. Sci."},{"issue":"4","key":"10.1016\/j.tranon.2021.101081_bib0105","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for Hsct-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.tranon.2021.101081_bib0106","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1055\/s-0039-1692721","article-title":"Linking complement activation, coagulation, and neutrophils in transplant-associated thrombotic microangiopathy","volume":"119","author":"Gavriilaki","year":"2019","journal-title":"Thromb Haemost."},{"issue":"12","key":"10.1016\/j.tranon.2021.101081_bib0107","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2013-05-501445","article-title":"Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"122","author":"Jodele","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.tranon.2021.101081_bib0108","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1182\/blood-2015-08-663435","article-title":"The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy","volume":"127","author":"Jodele","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.tranon.2021.101081_bib0109","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1055\/s-0040-1702225","article-title":"Pretransplant genetic susceptibility: clinical relevance in transplant-associated thrombotic microangiopathy","volume":"120","author":"Gavriilaki","year":"2020","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.tranon.2021.101081_bib0110","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/TP.0b013e31829807aa","article-title":"Renal Arteriolar C4d Deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy","volume":"96","author":"Laskin","year":"2013","journal-title":"Transplantation"},{"issue":"9323","key":"10.1016\/j.tranon.2021.101081_bib0111","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(02)08907-9","article-title":"Endothelial injury mediated by cytotoxic t lymphocytes and loss of microvessels in chronic graft versus host disease","volume":"359","author":"Biedermann","year":"2002","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.tranon.2021.101081_bib0112","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/sj.bmt.1703026","article-title":"Serum levels of soluble adhesion molecules in stem cell transplantation-related complications","volume":"27","author":"Matsuda","year":"2001","journal-title":"Bone Marrow Trans."},{"issue":"4","key":"10.1016\/j.tranon.2021.101081_bib0113","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1440-1797.2007.00915.x","article-title":"Clinicopathologic analysis of renal biopsies after haematopoietic stem cell transplantation","volume":"13","author":"Chan","year":"2008","journal-title":"Nephrology (Carlton)"},{"issue":"4","key":"10.1016\/j.tranon.2021.101081_bib0114","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3324\/haematol.2012.065599","article-title":"The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate","volume":"98","author":"Perez-Simon","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.tranon.2021.101081_bib0115","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.transproceed.2005.12.040","article-title":"Thrombotic nephropathy and pulmonary hypertension following autologous bone marrow transplantation in a patient with acute lymphoblastic leukemia: case report","volume":"38","author":"Perkowska-Ptasinska","year":"2006","journal-title":"Trans. Proc."},{"issue":"5","key":"10.1016\/j.tranon.2021.101081_bib0116","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/j.bbmt.2018.12.840","article-title":"Thrombotic microangiopathy following pediatric autologous hematopoietic cell transplantation: a report of significant end-organ dysfunction in eculizumab-treated survivors","volume":"25","author":"Schoettler","year":"2019","journal-title":"Biol Blood Marrow Trans."},{"issue":"10","key":"10.1016\/j.tranon.2021.101081_bib0117","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/s41409-018-0159-8","article-title":"High-dose carboplatin\/etoposide\/melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma","volume":"53","author":"Jodele","year":"2018","journal-title":"Bone Marrow Trans."},{"key":"10.1016\/j.tranon.2021.101081_bib0118","unstructured":"Overview and Clinical Assessment of the Complement System [Internet]. (Accessed December 2, 2020). 2020. Available from: https:\/\/www.uptodate.com\/contents\/overview-and-clinical-assessment-of-the-complement-system?search=complement&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1."},{"issue":"5","key":"10.1016\/j.tranon.2021.101081_bib0119","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.bbmt.2018.01.009","article-title":"Early increase in complement terminal pathway activation marker Sc5b-9 is predictive for the development of thrombotic microangiopathy after stem cell transplantation","volume":"24","author":"Horvath","year":"2018","journal-title":"Biol Blood Marrow Trans."},{"issue":"11","key":"10.1016\/j.tranon.2021.101081_bib0120","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00277-017-3092-9","article-title":"Plasma levels of complement activation fragments C3b and Sc5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation","volume":"96","author":"Qi","year":"2017","journal-title":"Ann. Hematol."},{"issue":"3","key":"10.1016\/j.tranon.2021.101081_bib0121","doi-asserted-by":"crossref","first-page":"e28070","DOI":"10.1002\/pbc.28070","article-title":"The alternative complement pathway activation product ba as a marker for transplant-associated thrombotic microangiopathy","volume":"67","author":"Sartain","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.tranon.2021.101081_bib0122","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/bmt.2010.182","article-title":"Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-Sct","volume":"46","author":"Laskin","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.tranon.2021.101081_bib0123","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bbmt.2005.06.001","article-title":"Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"11","author":"Ho","year":"2005","journal-title":"Biol Blood Marrow Trans."},{"key":"10.1016\/j.tranon.2021.101081_bib0124","series-title":"Diagnostic Criteria for Hematopoietic Stem Cell Transplant-Associated Microangiopathy: Results of a Consensus Process By an International Working Group","author":"Ruutu","year":"2007"},{"issue":"8","key":"10.1016\/j.tranon.2021.101081_bib0125","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/TP.0b013e3181f24e8d","article-title":"Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation","volume":"90","author":"Cho","year":"2010","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.tranon.2021.101081_bib0126","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: diagnosis and management of Hsct-associated thrombotic microangiopathy as multi-system endothelial injury","volume":"29","author":"Jodele","year":"2015","journal-title":"Blood Rev."},{"issue":"1","key":"10.1016\/j.tranon.2021.101081_bib0127","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/1076029615598221","article-title":"Hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"22","author":"Elsallabi","year":"2016","journal-title":"Clin. Appl. Thromb Hemost."},{"issue":"6","key":"10.1016\/j.tranon.2021.101081_bib0128","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1681\/ASN.V661661","article-title":"Evaluation of renal function in 60 long-term survivors of bone marrow transplantation","volume":"6","author":"Leblond","year":"1995","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.tranon.2021.101081_bib0129","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbmt.2018.08.016","article-title":"Therapeutic plasma exchange does not improve renal function in hematopoietic stem cell transplantation-associated thrombotic microangiopathy: an institutional experience","volume":"25","author":"Sartain","year":"2019","journal-title":"Biol Blood Marrow Trans."},{"issue":"3","key":"10.1016\/j.tranon.2021.101081_bib0130","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.transci.2007.03.004","article-title":"Abo-incompatible allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning: close association with transplant-associated microangiopathy","volume":"36","author":"Worel","year":"2007","journal-title":"Transfus. Apher. Sci."},{"issue":"3","key":"10.1016\/j.tranon.2021.101081_bib0131","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1537-2995.2012.03776.x","article-title":"Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy?","volume":"53","author":"Jodele","year":"2013","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.tranon.2021.101081_bib0132","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/sj.bmt.1703414","article-title":"Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation","volume":"29","author":"Corti","year":"2002","journal-title":"Bone Marrow Trans."},{"issue":"9","key":"10.1016\/j.tranon.2021.101081_bib0133","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.bmt.1702648","article-title":"Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing bone marrow transplantation","volume":"26","author":"Uderzo","year":"2000","journal-title":"Bone Marrow Trans."},{"issue":"3","key":"10.1016\/j.tranon.2021.101081_bib0134","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.2042-7158.1995.tb05789.x","article-title":"Defibrotide protects endothelial cells, but not L929 tumour cells, from tumour necrosis factor-alpha-mediated cytotoxicity","volume":"47","author":"Schroder","year":"1995","journal-title":"J. Pharm. Pharmacol."},{"issue":"9823","key":"10.1016\/j.tranon.2021.101081_bib0135","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","article-title":"Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial","volume":"379","author":"Corbacioglu","year":"2012","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.tranon.2021.101081_bib0136","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s00467-017-3803-4","article-title":"Thrombotic microangiopathy following haematopoietic stem cell transplant","volume":"33","author":"Seaby","year":"2018","journal-title":"Pediatr. Nephrol."},{"issue":"10","key":"10.1016\/j.tranon.2021.101081_bib0137","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/sj.bmt.1705657","article-title":"Life-threatening hemolytic-uremic syndrome treated with rituximab in an allogeneic bone marrow transplant recipient","volume":"39","author":"Ostronoff","year":"2007","journal-title":"Bone Marrow Trans."},{"issue":"7","key":"10.1016\/j.tranon.2021.101081_bib0138","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.bbmt.2010.02.006","article-title":"Chronic kidney disease, thrombotic microangiopathy, and hypertension following T Cell-depleted hematopoietic stem cell transplantation","volume":"16","author":"Glezerman","year":"2010","journal-title":"Biol. Blood Marrow Trans."},{"issue":"4","key":"10.1016\/j.tranon.2021.101081_bib0139","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2215\/CJN.11470918","article-title":"Etiology and outcomes of thrombotic microangiopathies","volume":"14","author":"Bayer","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.tranon.2021.101081_bib0140","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/00007611-199506000-00021","article-title":"Microangiopathic hemolytic anemia as an initial presentation of metastatic cancer of unknown primary origin","volume":"88","author":"Lin","year":"1995","journal-title":"South Med. J."},{"issue":"4","key":"10.1016\/j.tranon.2021.101081_bib0141","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/MD.0b013e3182603598","article-title":"Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases","volume":"91","author":"Lechner","year":"2012","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.tranon.2021.101081_bib0142","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0889-8588(05)70343-9","article-title":"Hemolytic disorders associated with cancer","volume":"10","author":"Rytting","year":"1996","journal-title":"Hematol Oncol Clin North Am."},{"issue":"8","key":"10.1016\/j.tranon.2021.101081_bib0143","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1634\/theoncologist.2009-0067","article-title":"Cancer awareness in atypical thrombotic microangiopathies","volume":"14","author":"Oberic","year":"2009","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.tranon.2021.101081_bib0144","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1634\/theoncologist.12-1-11","article-title":"Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: a report of 10 patients and a systematic review of published cases","volume":"12","author":"Francis","year":"2007","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.tranon.2021.101081_bib0145","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1056\/NEJM199908193410807","article-title":"Disseminated intravascular coagulation","volume":"341","author":"Levi","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2021.101081_bib0146","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12959-018-0168-2","article-title":"Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy","volume":"16","author":"Wada","year":"2018","journal-title":"Thromb J."},{"issue":"3","key":"10.1016\/j.tranon.2021.101081_bib0147","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.kint.2016.09.045","article-title":"Thrombotic microangiopathy associated with monoclonal gammopathy","volume":"91","author":"Ravindran","year":"2017","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.tranon.2021.101081_bib0148","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/MNH.0000000000000201","article-title":"Spectrum of manifestations of monoclonal gammopathy-associated renal lesions","volume":"25","author":"Sethi","year":"2016","journal-title":"Curr. Opin. Nephrol. Hypertens"},{"issue":"10","key":"10.1016\/j.tranon.2021.101081_bib0149","doi-asserted-by":"crossref","first-page":"E250","DOI":"10.1002\/ajh.25569","article-title":"Monoclonal gammopathy-associated thrombotic microangiopathy","volume":"94","author":"Yui","year":"2019","journal-title":"Am. J. Hematol."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523321000735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523321000735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T14:43:21Z","timestamp":1761835401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523321000735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":149,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1936523321000735"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2021.101081","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombotic microangiopathy in oncology \u2013 a review","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2021.101081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101081"}}